Chris is a Venture Partner based in our San Francisco Bay Area office, working with portfolio companies on their engagement with Wall Street and their overall financing strategy and execution. Chris spent over 20 years in executive management at biotech companies and investment banking. He has taken companies public, from both the company and the banking side, and has sold two companies in billion-dollar M&A transactions.
Chris raised $2.3BN in over 20 financing transactions which included venture rounds, crossovers, IPOs, follow-ons, converts and equity lines of credit. He was instrumental in gaining equity research coverage from 30 sell-side analysts, as well as developing a broad network of private and public institutional life sciences investors.
Chris has built and evolved his teams from private to public company finance organizations. In addition, he was involved with scaling one company to over 700 employees including the buildout of a US specialty salesforce. Chris previously was selected to Institutional Investor’s America’s Best CFOs list for the Biotechnology sector. He currently sits on the Board of Surrozen, Inc.
Prior Executive roles:
CFO at Principia Biopharma (PRNB), acquired by Sanofi; CFO at MAP Pharmaceuticals (MAPP), acquired by Allergan; Vice President, Treasury and Investor Relations at CV Therapeutics (CVTX), acquired by Gilead
Prior Investment Banking roles:
JP Morgan (San Francisco and New York)
Chris received his BS in Operations Research and Industrial Engineering from Cornell University
Biotech companies go through numerous transformative events including pre-clinical to clinical, privately held to publicly traded, and importantly R&D to a commercial organization. We are excited to help SR One’s portfolio companies as they make that journey and to ultimately develop new therapies for patients in need.